| abstract |
A process for the preparation of 3-alpha-hydroxy-19-nor-5-alpha-pregnan-11,20-dione, which comprises reducing stereospecifically 19-nor-5-alpha-pregnan-3,11,20-trione with an iridium catalyst reduction system, said system being prepared from a trivalent phosphorous compound, an iridium compound and water in the presence or absence of said steroid. (Machine-translation by Google Translate, not legally binding) |